Biosensors: Morgan Stanley recommends counter as top pick for 2012.
House expect further expansion of its distribution network in international mkts, benefiting from the advanced technologies of its flagship product, BioMatrix.
In addition, BIG expects to receive CE mark approval for its core pipeline product, BioFreedom, from the EU in 2012, which should be the key catalyst for the next 12-24 mths.
No comments:
Post a Comment